RNA-seq data with clinically characterized tissue
Select oncology tissue from TriStar’s repository with the treatment history and follow-up relevant to your RNA-seq study. Explore cohorts with optional expression datasets, or discuss additional RNA profiling on selected specimens.
THE INTEGRATED SERVICES APPROACH
Samples, services and pathology expertise through one partner
Repository samples
Selected for your study
- Fewer handoffs
- Spend less time coordinating samples and additional work across providers.
- Pathology-informed decisions
- Connect tissue suitability, assay selection and interpretation.
- Coordinated sample use
- Plan tissue allocation and laboratory work together, with one point of contact.
EXPRESSION & CLINICAL CONTEXT
Study gene expression in a defined treatment cohort
NSCLC with second-line immunotherapy follow-up
TA4301 connects a defined NSCLC tissue collection with second-line immuno-oncology follow-up. RNA-seq, GeoMx protein and RNA panels, and DAB IHC data are optional additions to the collection.
- Tissue collection
- NSCLC tissue microarray
- Treatment context
- Second-line immunotherapy follow-up
- Optional datasets
- RNA-seq, GeoMx protein/RNA and DAB IHC
TISSUE MICROARRAYS
TMAs with treatment follow-up and optional RNA-seq
These tissue microarrays (TMAs) offer optional RNA-seq datasets. Dataset coverage and accompanying clinical fields are reviewed for the array you select.
DESIGN THE COMPARISON
Connect expression, tissue and treatment records
YOUR SELECTED COHORT
Expression data in its biological context
Specify the comparison before selecting samples: a treatment group, response category or molecularly defined subset.
Explore donor data- Tissue characteristics
- Indication, histology and tumor content help define the sampled material.
- Clinical annotations
- Review the available treatment history, response and follow-up fields.
- Molecular context
- Consider existing IHC or other molecular findings alongside expression data.
ADD RNA PROFILING
Assess the tissue for the RNA analysis you need
Pathology review informs sample selection
Review tumor content, tissue composition and necrosis alongside the available RNA quality information. These factors help determine which specimens are appropriate for the planned analysis.
- Existing qualification
- Selected tissue has RNA-ISH control information; it does not by itself establish RNA-seq suitability.
- Additional profiling
- Agree the RNA assay, specimen requirements and data outputs for the selected tissue.
Work with our experienced scientific team to tailor biospecimens, data, and integrated services to your research needs.
Our approach begins with our customers’ science.
We focus our acquisition on patient cohorts that meet the needs of biopharma, clinical, and translational researchers.
Plan your study
Build a tissue cohort for RNA-seq research
Share your indication, treatment or outcome groups, cohort size and tissue requirements. We’ll review repository cases and available datasets, and discuss additional RNA profiling where needed.